Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

NeoPath, Inc.

NeoPath, Inc. Acta Cytologica NeoPath AutoPap 300 Automatic Pap Screener System Stanley F. Patten, Jr., M.D., Ph.D., F.I.A.C., James S. J. Lee, Ph.D., and Alan C. Nelson, Ph.D. NeoPath, Inc., has developed technologies to auto- Under certain circumstances, a cytopathology labo- mate the interpretation of cervical cytologic smears. ratory may wish to utilize the AutoPap QC System The company received Food and Drug Administra- in an adjunctive mode, where less than 100% of pre- tion (FDA) approval of its premarket approval ap- viously screened normal and satisfactory smears plication (PMA) on September 29, 1995, for com- are examined. Recent analyses in this configuration mercialization of the AutoPap 300 QC Automatic suggest that the highest cost-benefit ratio lies at a Pap Screener System (AutoPap QC System) to auto- 20% review rate. The physical configuration of the matically analyze and classify cervical cytologic AutoPap QC System, which includes the device it- smears for quality control purposes. An AutoPap self and a workstation composed of a computer, 300 Automatic Pap Screener System (AutoPap Pri- monitor, keyboard, mouse and pad, tape drive, mary Screener System), to be utilized to automati- modem and printer, is illustrated in Figure 1. The cally analyze and classify cytologic smears http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Cytologica Karger

NeoPath, Inc.

Download PDF
8 pages

Loading next page...
 
/lp/karger/neopath-inc-90HZqmSr5n

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1996 S. Karger AG, Basel
ISSN
0001-5547
eISSN
1938-2650
DOI
10.1159/000333584
Publisher site
See Article on Publisher Site

Abstract

Acta Cytologica NeoPath AutoPap 300 Automatic Pap Screener System Stanley F. Patten, Jr., M.D., Ph.D., F.I.A.C., James S. J. Lee, Ph.D., and Alan C. Nelson, Ph.D. NeoPath, Inc., has developed technologies to auto- Under certain circumstances, a cytopathology labo- mate the interpretation of cervical cytologic smears. ratory may wish to utilize the AutoPap QC System The company received Food and Drug Administra- in an adjunctive mode, where less than 100% of pre- tion (FDA) approval of its premarket approval ap- viously screened normal and satisfactory smears plication (PMA) on September 29, 1995, for com- are examined. Recent analyses in this configuration mercialization of the AutoPap 300 QC Automatic suggest that the highest cost-benefit ratio lies at a Pap Screener System (AutoPap QC System) to auto- 20% review rate. The physical configuration of the matically analyze and classify cervical cytologic AutoPap QC System, which includes the device it- smears for quality control purposes. An AutoPap self and a workstation composed of a computer, 300 Automatic Pap Screener System (AutoPap Pri- monitor, keyboard, mouse and pad, tape drive, mary Screener System), to be utilized to automati- modem and printer, is illustrated in Figure 1. The cally analyze and classify cytologic smears

Journal

Acta Cytologica – Karger

Published: Jan 1, 2011

Keywords: cervical smears; mass screening; image analysis; computer-assisted; laboratory diagnosis

There are no references for this article.